Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study

Authors: Cheng-Che Shen, Li-Yu Hu, Albert C. Yang, Yung-Yen Chiang, Jeng-Hsiu Hung, Shih-Jen Tsai

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Pelvic inflammatory disease (PID) is characterized by infection and inflammation of the upper genital tract in women and is associated with health sequelae. We used a nationwide population-based retrospective cohort study to explore the relationship between PID and the subsequent development of gynecological cancers including ovarian, breast or uterine cancer.

Methods

We identified subjects diagnosed with PID between January 1st, 2000 and December 31st, 2002 in the Taiwan National Health Insurance Research Database. A comparison cohort constructed for patients without PID were matched according to age and sex. All PID patients and control groups were observed until diagnosed with ovarian, breast or uterine cancer, or until death, withdrawal from the NHI system, or until December 31st, 2009.

Results

The PID cohort consisted of 32,268 patients, and an equal number of matched controls without PID. The adjusted hazard ratio (HR) of ovarian, breast or uterine cancer in subjects with PID were: HR 1.326 (95 % confidence interval: 0.775–2.269), HR: 1.039 (95 % confidence interval: 0.862–1.252), and HR: 1.439 (95 % confidence interval: 0.853–2.426) respectively in comparison with controls during follow-up.

Conclusions

This large nationwide population-based cohort study suggests that there is no increased risk for ovarian, breast or uterine cancer among women who have PID compared to a matching population.
Appendix
Available only for authorised users
Literature
1.
Crossman SH. The challenge of pelvic inflammatory disease. Am Fam Physician. 2006;73(5):859–64.PubMed
2.
Mitchell C, Prabhu M. Pelvic inflammatory disease: current concepts in pathogenesis, diagnosis and treatment. Infect Dis Clin North Am. 2013;27(4):793–809.CrossRefPubMed
3.
Gradison M. Pelvic inflammatory disease. Am Fam Physician. 2012;85(8):791–6.PubMed
4.
Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomark Prev. 1995;4(5):447–51.
5.
Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(8):667–9.PubMed
6.
Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4.CrossRefPubMed
7.
van de Laar R, Massuger LF. Pelvic inflammatory disease and ovarian cancer. Lancet Oncol. 2011;12(13):1184. author reply 1184-1185.CrossRefPubMed
8.
Cheong KM. Pelvic inflammatory disease and ovarian cancer. Lancet Oncol. 2011;12(13):1183–4. author reply 1184-1185.CrossRefPubMed
9.
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–14.CrossRefPubMed
10.
Shen CC, Yang AC, Hung JH, Hu LY, Tsai SJ. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist. 2015;20(1):45–9.CrossRefPubMed
11.
Hung JH, Hu LY, Tsai SJ, Yang AC, Huang MW, Chen PM, Wang SL, Lu T, Shen CC. Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study. PLoS ONE. 2014;9(5):e97041.CrossRefPubMedPubMedCentral
12.
Lee YT, Hu LY, Shen CC, Huang MW, Tsai SJ, Yang AC, Hu CK, Perng CL, Huang YS, Hung JH. Risk of psychiatric disorders following irritable bowel syndrome: a nationwide population-based cohort study. PLoS ONE. 2015;10(7):e0133283.CrossRefPubMedPubMedCentral
13.
Paragh G, Seres I, Harangi M, Fulop P. Dynamic interplay between metabolic syndrome and immunity. Adv Exp Med Biol. 2014;824:171–90.CrossRefPubMed
14.
Roep BO, Tree TI. Immune modulation in humans: implications for type 1 diabetes mellitus. Nat Rev Endocrinol. 2014;10(4):229–42.CrossRefPubMed
15.
Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor - a review. Placenta. 2008;29 Suppl B:169–77.CrossRefPubMed
16.
Haggerty CL, Totten PA, Tang G, Astete SG, Ferris MJ, Norori J, Bass DC, Martin DH, Taylor BD, Ness RB. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016;92(6):441–6.
17.
Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol. 1980;138(7 Pt 2):880–92.CrossRefPubMed
18.
19.
Rosin MP, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res. 1994;54(7 Suppl):1929s–33.PubMed
20.
Giraud J, Coiffic J, Poulain P, Kerisit J. High prevalence of cervical intra-epithelial neoplasia in women treated for pelvic inflammatory disease. Eur J Obstet Gynecol Reprod Biol. 1998;81(1):51–4.CrossRefPubMed
21.
Skapinyecz J, Smid I, Horvath A, Jeney C, Kardos L, Kovacs P. Pelvic inflammatory disease is a risk factor for cervical cancer. Eur J Gynaecol Oncol. 2003;24(5):401–4.PubMed
22.
Hsu MI, Lin HW. Risk of colorectal cancer in women with pelvic inflammatory disease: a matched cohort study. BJOG. 2014;121(3):337–42.CrossRefPubMed
23.
Bevan CD, Johal BJ, Mumtaz G, Ridgway GL, Siddle NC. Clinical, laparoscopic and microbiological findings in acute salpingitis: report on a United Kingdom cohort. Br J Obstet Gynaecol. 1995;102(5):407–14.CrossRefPubMed
Metadata
Title
Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study
Authors
Cheng-Che Shen
Li-Yu Hu
Albert C. Yang
Yung-Yen Chiang
Jeng-Hsiu Hung
Shih-Jen Tsai
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2857-1

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Study protocol

Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study

Research article

Comparative analysis of copy number variations in ulcerative colitis associated and sporadic colorectal neoplasia

Research article

Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers

Research article

The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome

Research article

Breast cancer literacy among higher secondary students: results from a cross-sectional study in Western Nepal

Research article

Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits